MX2009003400A - Compuestos antidiabeticos. - Google Patents

Compuestos antidiabeticos.

Info

Publication number
MX2009003400A
MX2009003400A MX2009003400A MX2009003400A MX2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A
Authority
MX
Mexico
Prior art keywords
peptidomimetics
antidiabetic compounds
glp
sub
found
Prior art date
Application number
MX2009003400A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Mukul R Jain
Rajesh H Bahekar
Pankaj Ramanbhai Patel
Kaushik M Banerjee
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2009003400A publication Critical patent/MX2009003400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

La presente invención proporciona nuevos peptidomiméticos de fórmula (I), que principalmente actúan como secretagogos de insulina dependiente de glucosa. Por otra parte, se encontró que estos peptidomiméticos muestran actividad antagonista respecto al receptor del glucagón y también actividad agonista respecto al receptor del GLP-1. A-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-B (I).
MX2009003400A 2006-10-03 2007-09-28 Compuestos antidiabeticos. MX2009003400A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1632MU2006 2006-10-03
IN1965MU2006 2006-11-30
IN423MU2007 2007-03-06
PCT/IN2007/000457 WO2008062457A2 (en) 2006-10-03 2007-09-28 Antidiabetic compounds

Publications (1)

Publication Number Publication Date
MX2009003400A true MX2009003400A (es) 2009-04-28

Family

ID=39430173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003400A MX2009003400A (es) 2006-10-03 2007-09-28 Compuestos antidiabeticos.

Country Status (9)

Country Link
US (1) US8841413B2 (es)
EP (1) EP2084182B1 (es)
JP (1) JP5247708B2 (es)
AU (1) AU2007323035B2 (es)
CA (1) CA2665033C (es)
DK (1) DK2084182T3 (es)
MX (1) MX2009003400A (es)
NZ (1) NZ576023A (es)
WO (1) WO2008062457A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883963B2 (en) * 2007-12-11 2014-11-11 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX2011005874A (es) * 2008-12-05 2011-06-27 Glaxo Group Ltd Metodos para seleccionar polipeptidos resistentes a proteasa.
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
EP2491054A2 (en) 2009-10-22 2012-08-29 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
SG191759A1 (en) 2010-12-30 2013-08-30 Enanta Pharm Inc Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
US10988514B2 (en) 2016-04-01 2021-04-27 University Of Washington Polypeptdes capable of forming homo-oligomers with modular hydrogen bond network-mediated specificity and their design
CA3076392A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. Methods for the treatment of cysteamine sensitive disorders
CN111171135B (zh) * 2018-11-12 2023-04-07 天津药物研究院有限公司 具有双重受体激动作用的胰高血糖素衍生肽及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005664A1 (en) * 2000-04-25 2004-01-08 Millennium Pharmaceuticals, Inc. Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
JP2005514337A (ja) 2001-10-18 2005-05-19 ブリストル−マイヤーズ　スクイブ　カンパニー ヒトグルカゴン様ペプチド−１模倣体、並びに糖尿病および関連疾患の処置におけるその使用
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
KR20080021636A (ko) * 2005-05-05 2008-03-07 카딜라 핼쓰캐어 리미티드 Ｇｌｐ-1 아고니스트인 신규 화합물

Also Published As

Publication number Publication date
AU2007323035B2 (en) 2011-11-24
US20130225488A1 (en) 2013-08-29
WO2008062457A8 (en) 2008-08-07
US8841413B2 (en) 2014-09-23
WO2008062457A2 (en) 2008-05-29
JP2010505820A (ja) 2010-02-25
CA2665033C (en) 2013-10-01
CA2665033A1 (en) 2008-05-29
JP5247708B2 (ja) 2013-07-24
WO2008062457A3 (en) 2008-10-02
EP2084182B1 (en) 2013-08-28
EP2084182A2 (en) 2009-08-05
DK2084182T3 (da) 2013-11-04
NZ576023A (en) 2012-06-29
AU2007323035A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
MX2009003400A (es) Compuestos antidiabeticos.
CA2707448C (en) Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
MY154798A (en) Fused cyclic compounds
MX2011011763A (es) Composiciones plaguicidas.
TW200626559A (en) Anilino-pyrimidine analogs
GEP20125506B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and use
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
WO2009043889A3 (en) Oxadiazole derivatives
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
TW200740814A (en) Compounds
WO2007146867A3 (en) Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
IL189996A0 (en) Stabilized glp-1 analogs
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX339557B (es) Composicion plaguicida y su uso.
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
TN2009000536A1 (en) Novel herbicides
WO2007017892A3 (en) Novel compounds as glp-i agonists
UA101297C2 (ru) Замещенное циклическое соединение, способ его получения и его медицинское применение
WO2009006267A3 (en) N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
MD4009C2 (ro) Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
UA87255C2 (en) Use of n-(2-(morpholine-4-yl)propyl)-2-naphthalimidoacetamide as interferone-inducing antiviral agent

Legal Events

Date Code Title Description
FG Grant or registration